<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39430626</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-5126</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JAAD case reports</Title><ISOAbbreviation>JAAD Case Rep</ISOAbbreviation></Journal><ArticleTitle>Relapsing toxic epidermal necrolysis following COVID-19.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>26</EndPage><MedlinePgn>23-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdcr.2024.07.011</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Messele</LastName><ForeName>Feben</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of California, Irvine, Irvine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of California, Irvine, Irvine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Ajay N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of California, Irvine, Irvine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Michelle S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of California, Irvine, Irvine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojek</LastName><ForeName>Nathan W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of California, Irvine, Irvine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linden</LastName><ForeName>Kenneth G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of California, Irvine, Irvine, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAAD Case Rep</MedlineTA><NlmUniqueID>101665210</NlmUniqueID><ISSNLinking>2352-5126</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SJS</Keyword><Keyword MajorTopicYN="N">Stevens-Johnson syndrome</Keyword><Keyword MajorTopicYN="N">TEN</Keyword><Keyword MajorTopicYN="N">relapsing</Keyword><Keyword MajorTopicYN="N">toxic epidermal necrolysis</Keyword></KeywordList><CoiStatement>Dr Min is on the advisory boards of Horizon, McGraw Hill, and BMS and is an investigator for Amgen, BI, MBS, and Priovant. Dr Rojek has served on the advisory board of Boehringer Ingelheim. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39430626</ArticleId><ArticleId IdType="pmc">PMC11488411</ArticleId><ArticleId IdType="doi">10.1016/j.jdcr.2024.07.011</ArticleId><ArticleId IdType="pii">S2352-5126(24)00277-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Frantz R., Huang S., Are A., Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina (Kaunas) 2021;57(9):895. doi: 10.3390/medicina57090895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57090895</ArticleId><ArticleId IdType="pmc">PMC8472007</ArticleId><ArticleId IdType="pubmed">34577817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou H., Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol. 2023;64(1):e1–e10. doi: 10.1111/ajd.13958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajd.13958</ArticleId><ArticleId IdType="pmc">PMC9878214</ArticleId><ArticleId IdType="pubmed">36484649</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis K.K., Dillan M.M., Sharma T.R., Piktel J. COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective cohort analysis. J Am Acad Dermatol. 2024;90(6):1300–1302. doi: 10.1016/j.jaad.2024.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2024.02.029</ArticleId><ArticleId IdType="pubmed">38423469</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley E.A., Zhang L., O’Hara J., Haertsch P., Maitz P. The seven-fold rise in incidence of Stevens-Johnson syndrome &amp; toxic epidermal necrolysis: associations with COVID-19 and the vaccine. Burns. 2024;50(1):87–92. doi: 10.1016/j.burns.2023.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2023.06.016</ArticleId><ArticleId IdType="pubmed">37730480</ArticleId></ArticleIdList></Reference><Reference><Citation>Malviya M., Barua S., Shenoy M.A., Ullah A.M. Paxlovid-associated Stevens-Johnson syndrome. Chest J. 2023;164(4):A2062–A2063. doi: 10.1016/j.chest.2023.07.1410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2023.07.1410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowndes S., Darby A., Mead G., Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002;13(12):1948–1950. doi: 10.1093/annonc/mdf350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdf350</ArticleId><ArticleId IdType="pubmed">12453865</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.C., Wang T.J., Lin M.H., Chen T.J. A review of the systemic treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biomedicines. 2022;10(9):2105. doi: 10.3390/biomedicines10092105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10092105</ArticleId><ArticleId IdType="pmc">PMC9495335</ArticleId><ArticleId IdType="pubmed">36140207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting W., Stone M.S., Racila D., Scofield R.H., Sontheimer R.D. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004;13(12):941–950. doi: 10.1191/0961203304lu2037sa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203304lu2037sa</ArticleId><ArticleId IdType="pubmed">15645750</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M., Zhang M., Hu W., Kong Q., Sang H., Xu X. A case of paraneoplastic pemphigus associated with Castleman’s disease. An Bras Dermatol. 2013;88(6 Suppl 1):11–14. doi: 10.1590/abd1806-4841.20132332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/abd1806-4841.20132332</ArticleId><ArticleId IdType="pmc">PMC3875984</ArticleId><ArticleId IdType="pubmed">24346868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappius R.H., Ufkes N.A., Thiers B.H. StatPearls [Internet] StatPearls Publishing; 2024. Paraneoplastic Pemphigus.</Citation><ArticleIdList><ArticleId IdType="pubmed">31536300</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>